CDK9 and neoplasm: SNS-032 (formerly BMS-387032) was originally discovered as a selective inhibitor against CDK2 by Bristol-Myers Squibb Pharmaceutical Research Institute (Stamford, CT).34 Subsequent studies revealed that SNS-032 inhibited the proliferation of tumor cells by interfering with CDK7 and CDK9 with IC50 of 62 and 4 nM respectively.11,32,35 More studies are needed to determine whether the strong anti-SARS-CoV-2 activity of SNS-032 also depends on the inhibition of CDK7 and/or CDK9.